Response rate to immunotherapy mainly immune checkpoint inhibitors (ICI) in solid tumors is limited. Therefore, there is a critical need to identify predictive markers of response (of specific drugs and of drug combinations) and to identify novel drug targets for combination therapies with ICI.
Protica Bio, is bio-convergence company aims to tackle these challenges through combining proteomics and computational biology.
CEO: Olga Nissan
